Suchergebnisse - "*Antirheumatic Agents"

PubPharm (525)

1

Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland : a nation-level study

enthalten in: Polish archives of internal medicine | 2024

von Stajszczyk, M. | Kwiatkowska, B. | Żuber, Z. | +1

2

Clinical features of patients with rheumatic and musculoskeletal diseases during the coronavirus disease 2019 pandemic and the association of its relapse with infection : Across-sectional study

enthalten in: International journal of rheumatic diseases | 2024

von Zhang, Y. | Xu, P. | Huang, J. | +1

3

Infliximab Concentrations in Participants with Moderate to Severe COVID-19

enthalten in: Journal of clinical pharmacology | 2024

von Balevic, S. | Dandachi, D. | Dixon, D. | +4

4

OpenSAFELY : The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate

enthalten in: British journal of clinical pharmacology | 2024

von Brown, A. | Fisher, L. | Curtis, H. | +25

5

Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020 : A Systematic Review

enthalten in: Medicina (Kaunas, Lithuania) | 2024

von Schlegel, M. | Bachmann, S.

6

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)

enthalten in: Microbiology spectrum | 2024

von Frodlund, M. | Nived, P. | Chatzidionysiou, K. | +8

7

Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls

enthalten in: The Journal of rheumatology | 2024

von Eviatar, T. | Furer, V. | Polachek, A. | +14

8

Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022 : Analysis of the JCR COVID-19 registry in Japan

enthalten in: Modern rheumatology | 2024

von Kashiwado, Y. | Kimoto, Y. | Oku, K. | +5

9

Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients

enthalten in: Rheumatology (Oxford, England) | 2024

von Kashiwado, Y. | Kimoto, Y. | Ohshima, S. | +18

10

Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases

enthalten in: The Journal of rheumatology | 2024

von Kawano, Y. | Wang, X. | Patel, N. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[53]